Autopsy report · NCT05033522

Immunotherapy for Advanced Liver Cancer

“Sponsor unable to fund”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 11 months before it started.
• Suspended: paused, and may or may not restart.
• 150 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2, Phase 3

Sponsor

Mirror Biologics, Inc.

Sponsor type

Industry

Conditions

Hepatocellular Carcinoma

Interventions

AlloStim® immunotherapy; FOLFOX regimen; Sorafenib; Lenvatinib

Participants

150 (planned, not actual)

Sites

8

Countries

Malaysia, Thailand

Trials that died the same way

• The Effect of Theraworx Foam in Carpal Tunnel Syndrome
  “Lack of Funding from Sponsor” (87% match in meaning)
• RESPECT Heart Failure- RESpiratory Pattern Evaluation in Clinical Trials for HF
  “Funding from Sponsor did not come through” (84% match in meaning)
• Intraoperative Warming During Major Surgical Procedures Using the Esophageal Temperature Management System
  “Sponsor funding limitations” (79% match in meaning)
• Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use
  “Lost funding from sponsor” (79% match in meaning)
• A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
  “Sponsor lost funding” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.